Healthcare Industry News: drug-eluting stent
News Release - July 30, 2007
OrbusNeich Expands Global Sales and Marketing TeamCompany Appoints Two Interventional Cardiology Industry Professionals as Demand Increases for Genous(TM) Bio-engineered R stent(TM)
HONG KONG, July 30 (HSMN NewsFeed) -- OrbusNeich today announced the continued expansion of its global sales and marketing team with the additions of Massimo Chiesa and Per Arne Winberg to director level positions. Chiesa and Winberg have extensive experience in the interventional cardiology industry. Chiesa is based in Milan and will be director of sales and marketing for Western Europe, the Middle East and Latin America. Winberg is based in Copenhagen and will be director of sales and marketing for Northern and Eastern Europe. The additions come at a time that OrbusNeich is seeing increased demand in Europe for its Genous Bio-engineered R stent in light of physicians' concerns with drug eluting stents.
"The Genous stent is a logical choice for interventional cardiologists today," said Samuel Rasmussen, OrbusNeich's president and CEO. "With the recent release of very positive data from the e-HEALING registry and expected near term presentation of more data from several trials involving Genous, we're building a larger sales and marketing team to cover more ground, especially throughout Europe."
Prior to joining OrbusNeich, Chiesa was a European business director with EuroCor International. Before this, he held senior sales and marketing positions with Volcano Therapeutics, Jomed and SCIMed, which became part of Boston Scientific.
Before joining OrbusNeich, Winberg worked with Abbott Vascular, where he was director for sales and marketing for several regions in Europe and the United Kingdom. He also held director positions with Jomed and Cordis/Johnson & Johnson.
Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.
OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous Bio-engineered R stent, an antibody-coated device that is the first ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.
A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products in more than 60 countries. For more information, visit www.OrbusNeich.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.